ProCE Banner Activity

Nuovi dati sugli inibitori di BTK nella CLL e MCL: gli esperti discutono lEHA 2022

Clinical Thought
In questa intervista, due esperti discutono i dati degli studi clinici sugli inibitori di BTK nel trattamento della leucemia linfatica cronica (CLL) e del linfoma mantellare (MCL) presentati al Congresso EHA 2022.

Released: August 15, 2022

Expiration: August 14, 2023

No longer available for credit.

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Medical Doctor
Dep I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Provided by

ProCE Banner

Supporters

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Medical Doctor
Dep I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead Sciences, Janssen-Cilag, Roche; consultant/advisor: AbbVie, Gilead Sciences, Janssen-Cilag, Roche; researcher (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead Sciences, Janssen-Cilag, Roche.

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD: honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, Octapharma; travel grants: BeiGene, Janssen.